# Jenken Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jenken-biosciences

- Industry: Pharmaceuticals
- Headquarters: Durham, US
- Website: www.jenkenbio.com
- Total disclosed funding: $2M
- Latest round: Series A (Nov 20, 2006)
- Investors on record: 1

## About

Jenken Biosciences develops innovative biotechnology solutions aimed at enhancing agricultural productivity and sustainability through eco-friendly products.Founded in 2003 and headquartered in Durham, US, Jenken Biosciences specializes in biotechnology for agriculture. The company has pivoted to focus on bio-based fertilizers and soil amendments. In July 2007, it secured USD 0.140 mn in VENTURE DEBT from North Carolina Biotechnology Center, raising the total amount to USD 2.000 mn across two deals. The company was established independently and does not operate as a subsidiary of another entity.Jenken Bio specializes in developing innovative biotechnology solutions that enhance agricultural productivity and sustainability. Its core offerings include bio-based fertilizers and soil amendments that improve plant health and soil quality. Launched in 2021, these products address critical agricultural challenges, promoting resilience and reducing reliance on synthetic fertilizers among agricultural cooperatives and distributors in North America and Europe.Jenken Bio generates revenue through direct sales and partnerships with agricultural distributors, engaging in B2B transactions. Revenue primarily comes from its bio-fertilizers, reflecting the premium nature of its eco-friendly solutions. Clients often enter into bulk purchase agreements for consistent supply, and subscription plans are also available to maintain soil health over time.Looking ahead, Jenken Biosciences plans to expand its product line with new eco-friendly offerings designed for the agricultural sector. They aim to penetrate new markets in Asia and South America by 2025. The funding from the most recent deal in July 2007, amounting to USD 0.140 mn, will be utilized to support these product development initiatives and market expansion efforts.

## Funding rounds

- Series A, Nov 20, 2006, $2M — Cato BioVentures

## Investors

- Cato BioVentures (https://capitalatlas.ai/funds/cato-bioventures) — Series A